S287
Clinical - Breast
ESTRO 2026
Digital Poster 2747 Retrospective observational study of patients with luminal breast cancer in early stages: 10-year follow-up—Which luminal breast cancer relapse? MARIA BELEN RIOS POZO 1 , JORGE CONTRERAS MARTINEZ 1 , SIGFREDO E ROMERO ZOGHBI 1 , TAMARA DIAZ REDONDO 2 1 RADIATION ONCOLOGY, HOSPITAL UNIVERSITARIO REGIONAL DE MALAGA( CARLOS HAYA), MALAGA, Spain. 2 MEDICAL ONCOLOGY, HOSPITAL UNIVERSITARIO REGIONAL DE MALAGA( CARLOS HAYA), MALAGA, Spain Purpose/Objective: Breast cancer is a heterogeneous group of breast cancer, with molecular signatures of better prognoses and others of worse prognoses being found. Prosigna test provide the molecular BC subtype, an individualized prognostic score called “ROR score”. Our main objective is to analyze in 10 years which Luminal early BC patients have local and distant relapses. See if there is a correlation between ROR and relapse. As second objective is select this group of patients who relapse and analyze the presence of CAF S1 for a future study. Material/Methods: We performed a retrospective observational study from the two main hospitals in Málaga (Spain) We included 415 women 43-79 years with EBC defined as T1 or T2 primary breast cancer ,30 mm in the largest dimension) node negative. Molecular BC subtype analyzed by IHC and genomic platform Prosigna) The patients were treated with breast-conserving surgery with clear excision margins hypofractionated radiotherapy and adjuvant endocrine therapy. We followed them from 2014 to the present. Results: 415 patients. We made genetic platform Prosigna to all of them luminal A 55%, Luminal B 37%, Basal like 4.8% and Her2 3.6%. The median follow-up was 9.1 years. The cumulative incidence of recurrence in Luminal BC was 2.29% (44.4% locoregional 55.55% distant recurrence). In 55.55% of the patients that relapsed had a Prosigna test with high ROR score, in 11.11% of the patients that relapsed had a Prosigna test with an intermediate ROR score and in 33.33 of the patients that relapsed had a Prosigna test with a low ROR score. Conclusion: In our study the cumulative incidence of recurrence in Luminal BC was 2.29 % and the ROR score provided a good estimate of the risk of relapse. Currently we use genomic platforms as Prosigna to estimate the ROR and adapt treatments to the risk. However, until now there is no biological or translational study focusing on T1N0 luminal BC. Subsequently, there exists a real
Radiation doses ranged from 44 Gy to 66 Gy, depending on clinical indication.Overall, moderate– severe toxicity (> Grade 2) occurred in 59/472 (12.5%) and mild toxicity (Grade 1) in 254/472 (53.8%). By supportive therapy, moderate–severe events were observed in 15.6% (49/315) of the control group versus 6.4% (10/157) with LimpiAD® cream (p < 0.004), while mild toxicity occurred in 65.4% (206/315) and 30.6% (48/157), respectively (p < 0.001).Both groups showed lower toxicity rates than historical series, with LimpiAD® use resulting in roughly a 50% reduction in mild and moderate–severe reactions. Conclusion: In adjuvant whole-breast RT with advanced IMRT/VMAT techniques, LimpiAD® cream significantly reduced acute skin toxicity compared with standard emollients. Combining modern RT delivery with optimized skin care, such as LimpiAD®, whose patented HA c-40 forms a non-occlusive barrier that prevents fluid loss and maintains hydration, may enhance treatment tolerability and patient comfort. Prospective randomized trials are warranted to confirm these results. References: [1] Delaney et al., Cancer 2005;[2] Pignol et al., Radiother Oncol 2008;[3] Kole et al., Breast Cancer Res Treat 2022 Keywords: Supportive Care; Skin Toxicity; Whole- Breast RT
Made with FlippingBook - Share PDF online